Savara Reports First Quarter Financial Results and Provides

Pivotal Phase 3 IMPALA-2 Trial Remains On-Track


Company expects trial to be fully enrolled in June 2023, on-track to report top line data by end of 2Q 2024



48-week placebo-controlled trial is... | May 15, 2023

Related Keywords

Pharma Gmb , Matt Pauls , Nasdaq , Savara Inc , Linkedin , Twitter , Quarter Financial Results , Nebulizer System , Private Securities Litigation Reform Act , Consolidated Statements , Savara Inc Stock Exchange , News , Information , Press Release , Pivotal , Hase , , Trial , Remains , Xpects , O , The , Bully , Unrolled , N , Pune , Report , Top , Line , Data , Y , End , F , Q , Rial Svra Us8051111016 ,